# Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

> **NCT01514344** · PHASE2 · COMPLETED · sponsor: **Andres J. M. Ferreri** · enrollment: 20 (actual)

## Conditions studied

- Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma

## Interventions

- **DRUG:** intralesional rituximab
- **BIOLOGICAL:** supplemental autologous serum

## Key facts

- **NCT ID:** NCT01514344
- **Lead sponsor:** Andres J. M. Ferreri
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-10
- **Final completion:** 2019-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01514344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01514344, "Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01514344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*